Coherus Oncology
CHRS
135 hedge funds and large institutions have $143M invested in Coherus Oncology in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 24 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
1% less funds holding
Funds holding: 137 → 135 (-2)
2.16% less ownership
Funds ownership: 74.14% → 71.98% (-2.2%)
28% less capital invested
Capital invested by funds: $198M → $143M (-$54.8M)
32% less call options, than puts
Call options by funds: $219K | Put options by funds: $321K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.11M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.01M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.45M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.05M |
| 5 |
BlackRock
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$4.33M |
| 2 |
Temasek Holdings
Singapore
|
-$3.14M |
| 3 |
Morgan Stanley
New York
|
-$2.23M |
| 4 |
Millennium Management
New York
|
-$1.29M |
| 5 |
Two Sigma Investments
New York
|
-$1.26M |
CHRS Hedge Fund Activity: Q2 2024 in Review
135 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2024, worth a combined $143M — down 28% from $198M a quarter earlier.
Fund positioning in CHRS was balanced in Q2 2024: 24 funds opened new positions, 24 closed out, 47 added to existing stakes and 36 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.11M. The largest seller was Bank of America, cutting an estimated $4.33M.
- 135 institutional investors held Coherus Oncology (CHRS) as of Q2 2024, down from 137 in Q1 2024.
- Funds reported $143M of Coherus Oncology stock for Q2 2024, down 28% quarter-over-quarter.
- 24 funds opened new Coherus Oncology positions in Q2 2024 and 24 closed out, a net change of 0 holders.
- The largest Coherus Oncology buyer in Q2 2024 was Tang Capital Management, an estimated $2.11M added.
- The largest Coherus Oncology seller in Q2 2024 was Bank of America, an estimated $4.33M sold.
Based on aggregated 13F filings for Q2 2024.